Almirall, S.A. (BME:ALM)
11.28
-0.04 (-0.35%)
May 18, 2026, 4:16 PM CET
Almirall Revenue
Almirall had revenue of 292.40M EUR in the quarter ending March 31, 2026, with 2.20% growth. This brings the company's revenue in the last twelve months to 1.12B, up 9.04% year-over-year. In the year 2025, Almirall had annual revenue of 1.11B with 12.51% growth.
Revenue (ttm)
1.12B
Revenue Growth
+9.04%
P/S Ratio
2.17
Revenue / Employee
531.70K
Employees
2,108
Market Cap
2.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.11B | 123.91M | 12.51% |
| Dec 31, 2024 | 990.63M | 91.84M | 10.22% |
| Dec 31, 2023 | 898.79M | 20.28M | 2.31% |
| Dec 31, 2022 | 878.51M | 42.01M | 5.02% |
| Dec 31, 2021 | 836.50M | 22.01M | 2.70% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Grifols | 7.44B |
| Laboratorios Farmaceuticos Rovi | 741.09M |
| Faes Farma | 674.06M |
| Laboratorio Reig Jofre | 335.01M |
| Clínica Baviera | 304.91M |
| Prim, S.A. | 251.89M |
| Pharma Mar | 225.43M |
| Atrys Health | 144.31M |
Almirall News
- 6 days ago - Almirall SA (ALMRY) Q1 2026 Earnings Call Highlights: Strong Biologics Growth and Strategic ... - GuruFocus
- 7 days ago - Almirall Earnings Call Transcript: Q1 2026 - Transcripts
- 7 days ago - Almirall Continues Its Positive Trajectory in Q1 2026 in Line With Expectations – Led by 19.3% YoY Growth of Its European Dermatology Business - Business Wire
- 5 weeks ago - Almirall and Barcelona Supercomputing Center Expand Their Collaboration to Accelerate Innovation in Medical Dermatology - Business Wire
- 7 weeks ago - Almirall presents long-term interim results from Phase 3b ADlong study - TheFly
- 7 weeks ago - Almirall presents clinical, real-word data across portfolio at AAD meeting - TheFly
- 7 weeks ago - AAD 2026: Almirall Presents New Clinical and Real‑world Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and Acne - Business Wire
- 2 months ago - Almirall's 17th Skin Academy Highlights Scientific Advances in Inflammatory Skin Diseases and Skin Cancer, Patient-Reported Outcomes, and Holistic Care in Medical Dermatology - Business Wire